Journal of Neuroimmunology
Volume 217, Issue 1 , Pages 95-101 , 10 December 2009

Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases

  • Johannes Brettschneider

      Affiliations

    • Department of Neurology, University of Ulm, Ulm, Germany
    • The authors contributed equally to the study and appear in alphabetical order.
    • ,
  • Troy D. Jaskowski

      Affiliations

    • Immunology, Research & Development, ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA
    • The authors contributed equally to the study and appear in alphabetical order.
    • ,
  • Hayrettin Tumani

      Affiliations

    • Department of Neurology, University of Ulm, Ulm, Germany
    • ,
  • Sana Abdul

      Affiliations

    • Department of Neurology, University of Ulm, Ulm, Germany
    • ,
  • Dee Husebye

      Affiliations

    • Department of Neurology, University of Utah, Salt Lake City, UT, USA
    • ,
  • Haniah Seraj

      Affiliations

    • Department of Neurology, University of Utah, Salt Lake City, UT, USA
    • ,
  • Harry R. Hill

      Affiliations

    • Departments of Pathology, Pediatrics and Medicine, University of Utah, Salt Lake City, UT, USA
    • ,
  • Ella Fire

      Affiliations

    • Glycominds Ltd., Lod, Israel
    • ,
  • Larissa Spector

      Affiliations

    • Glycominds Ltd., Lod, Israel
    • ,
  • Jennifer Yarden

      Affiliations

    • Glycominds Ltd., Lod, Israel
    • ,
  • Nir Dotan

      Affiliations

    • Glycominds Ltd., Lod, Israel
    • ,
  • John W. Rose

      Affiliations

    • Neurovirology Research Laboratory VASLCHCS and the Department of Neurology, University of Utah, Salt Lake City, UT, USA
    • Corresponding Author InformationCorresponding author. Neurovirology Research Laboratory VASLCHCS and the Department of Neurology, University of Utah, Salt Lake City, UT, 84112, USA. Tel.: +1 801 584 1292; fax: +1 801 584 5654.

Received 17 May 2009 ,Revised 26 July 2009 ,Accepted 28 July 2009.

References 

  1. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N. Engl. J. Med. 2003;349:139–145
  2. Berger T, Reindl M. Multiple sclerosis: disease biomarkers as indicated by pathophysiology. J. Neurol. Sci. 2007;259:21–26
  3. Boullerne AI, Rodriguez JJ, Touil T, Brochet B, Schmidt S, Abrous ND, et al. Anti-S-nitrosocysteine antibodies are a predictive marker for demyelination in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J. Neurosci. 2002;22:123–132
  4. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med. 2002;346:158–164
  5. Brousseau KM, Arciniegas DB, Carmosino MJ, Corboy JR. The differential diagnosis of Axis I psychopathology presenting to a university-based multiple sclerosis clinic. Mult. Scler. 2007;13:749–753
  6. Dalton CM, Brex PA, Miszkiel KA, Hickman SJ, MacManus DG, Plant GT, et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann. Neurol. 2002;52:47–53
  7. Daumer M, Neuhaus A, Lederer C, Scholz M, Wolinsky JS, Heiderhoff M Sylvia Lawry Centre for Multiple Sclerosis Research. Prognosis of the individual course of disease—steps in developing a decision support tool for multiple sclerosis. BMC Med. Inform. Decis. Mak. 2007;7:11
  8. Duan B, Morel L. Role of B-1a cells in autoimmunity. Autoimmun. Rev. 2006;5:403–408
  9. Fadil H, Kelley RE, Gonzalez-Toledo E. Differential diagnosis of multiple sclerosis. Int. Rev. Neurobiol. 2007;79:393–422
  10. Fisniku LK, Brex P, Altman DR, Miszkiel KA, Benton CE, Lanyon R, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008;131:808–817
  11. Freedman MS, Laks J, Dotan N, Altstock RT, Dukler A, Sindic CJM. Anti-α-glucose based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event. Mult. Scler. 2009;15:422–430
  12. Hawa M, Beyan H, Leslie RD. Principles of autoantibodies as disease-specific markers. Autoimmunity. 2004;37:253–256
  13. Goldsby RA, Kindt TJ, Osborne BA. In: Kuby Immunology. fourth edition. New York: W.H. Freeman and Company; 2000;p. 273
  14. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N. Engl. J. Med. 2000;343:898–904
  15. Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N. Engl. J. Med. 2007;356:371–378
  16. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106–2112
  17. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med.15,. 2005;202:473–477
  18. Lolli F, Mulinacci B, Carotenuto A, Bonetti B, Sabatino G, Mazzanti B, et al. An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2005;102:10273–10278
  19. Lolli F, Mazzanti B, Pazzagli M, Peroni E, Alcaro MC, Sabatino G, et al. The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis. J. Neuroimmunol. 2005;167:131–137
  20. Lucchinetti C. Pathological heterogeneity of idiopathic central nervous system inflammatory demyelinating disorders. Curr. Top. Microbiol. Immunol. 2008;318:19–43
  21. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001;50:121–127
  22. Menge T, Lalive PH, von Budingen HC, Cree B, Hauser SL, Genain CP. Antibody responses against galactocerebroside are potential stage-specific biomarker in multiple sclerosis. J. Allergy Clin. Immunol. 2005;116:453–459
  23. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005;4:281–288
  24. Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, Laursen H, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain. 2006;129:3165–3172
  25. Pelayo R, Tintoré M, Montalban X, Rovira A, Espejo C, Reindl M, et al. Antimyelin antibodies with no progression to multiple sclerosis. N. Engl. J. Med. 2007;356:426–428
  26. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann. Neurol. 2005;58:840–846
  27. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983;13:227–231
  28. Prince HE. Biomarkers for diagnosing and monitoring autoimmune diseases. Biomarkers. 2005;10(Suppl 1):S44–S49
  29. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. Reference distributions for immunoglobulins A, G, and M: a practical, simple, and clinically relevant approach in a large cohort. J. Clin. Lab. Anal. 1998;12:363–370
  30. Sailer M, O'Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, McDonald WI, et al. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology. 1999;52:599–606
  31. Schwarz M, Spector L, Gortler M, Weishaus O, Glass-Marmor L, Karni A, et al. Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing–remitting multiple sclerosis. J Neurol. Sci. 2006;244:59–68
  32. Tintoré M, Rovira A, Río J, Nos C, Grivé E, Sastre-Garriga J, et al. New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology. 2003;60:27–30
  33. Thrower BW. Clinically isolated syndromes: predicting and delaying multiple sclerosis. Neurology. 2007;68:S12–S15

PII: S0165-5728(09)00301-4

doi: 10.1016/j.jneuroim.2009.07.017

Journal of Neuroimmunology
Volume 217, Issue 1 , Pages 95-101 , 10 December 2009

Article Tools

* Image Usage & Resolution